Clinical benefit from resection of recurrent glioblastomas: Results of a multicenter study including 503 patients with recurrent glioblastomas undergoing surgical resection

Neuro-Oncology

Volumn 18, Issue 1, 2016, Pages 96-104

  Ringel, Florian ^a   Pape, Haiko ^a   Sabel, Michael ^b   Krex, Dietmar ^c   Bock, Hans Christoph ^d   Misch, Martin ^e   Weyerbrock, Astrid ^f   Westermaier, Thomas ^g   Senft, Christian ^h   Schucht, Philippe ⁱ   Meyer, Bernhard ^a   Simon, Matthias ^j  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^d UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f UNIVERSITY OF FREIBURG   (Germany)

^g UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^h GOETHE UNIVERSITY   (Germany)

ⁱ UNIVERSITY OF BERN   (Switzerland)

^j UNIVERSITY OF BONN   (Germany)

more..

Author keywords

glioblastoma; overall survival; recurrent tumor; surgical resection

Indexed keywords

BEVACIZUMAB; CARMUSTINE; LOMUSTINE; NIMUSTINE; TEMOZOLOMIDE;

ADJUVANT THERAPY; ADOLESCENT; ADULT; AGE; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER LOCALIZATION; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; FEMALE; GLIOBLASTOMA; HUMAN; KARNOFSKY PERFORMANCE STATUS; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); NEUROSURGERY; ONCOLOGICAL PARAMETERS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT ASSESSMENT; POSTOPERATIVE COMPLICATION; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PRIMARY TUMOR; REOPERATION; RETROSPECTIVE STUDY; SURVIVAL TIME; TREATMENT RESPONSE; BRAIN NEOPLASMS; CLINICAL TRIAL; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; PROCEDURES; PROGNOSIS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BRAIN NEOPLASMS; FEMALE; GLIOBLASTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; NEUROSURGICAL PROCEDURES; PROGNOSIS; REOPERATION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84960426654     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov145     Document Type: Article

References (50)

1. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987-996.
2. Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma-Are we there yet?. Neuro Oncol. 2013;15(1):4-27.
3. Combs SE, Thilmann C, Edler L, et al. Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-Term results in 172 patients treated in a single institution. J Clin Oncol. 2005; 23(34):8863-8869.
4. Patel M, Siddiqui F, Jin JY, et al. Salvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival. J Neurooncol. 2009;92(2):185-191.
5. Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent malignant glioma. BMC Cancer. 2005;5:55.
6. Combs SE, Edler L, Rausch R, et al. Generation and validation of a prognostic score to predict outcome after re-irradiation of recurrent glioma. Acta Oncol. 2013;52(1):147-152.
7. Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001;95(2):190-198.
8. Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. J Neurosurg. 2011; 115(1):3-8.
9. Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery. 2008;62(3):564-576; discussion 564-576.
10. Ammirati M, Galicich JH, Arbit E, et al. Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery. 1987;21(5):607-614.
11. Barker FG II, Chang SM, Gutin PH, et al. Survival and functional status after resection of recurrent glioblastoma multiforme. Neurosurgery. 1998;42(4):709-720; discussion 720-703.
12. Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?. Neuro Oncol. 2011;13(10):1118-1124.
13. Harsh GRT, Levin VA, Gutin PH, et al. Reoperation for recurrent glioblastoma and anaplastic astrocytoma. Neurosurgery. 1987; 21(5):615-621.
14. Helseth R, Helseth E, Johannesen TB, et al. Overall survival, prognostic factors, and repeated surgery in a consecutive series of 516 patients with glioblastoma multiforme. Acta Neurol Scand. 2010;122(3):159-167.
15. Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma. J Neurosurg. 2013;118(6):1224-1231.
16. Muhling M, Krage J, Hussein S, et al. Indication for repeat surgery of glioblastoma: influence of progress of disease. Front Radiat Ther Oncol. 1999;33:192-201.
17. Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralbl Neurochir. 2001;62(2):43-47.
18. Stromblad LG, Anderson H, Malmstrom P, et al. Reoperation for malignant astrocytomas: personal experience and a review of the literature. Br J Neurosurg. 1993;7(6):623-633.
19. Vick NA, Ciric IS, Eller TW, et al. Reoperation for malignant astrocytoma. Neurology. 1989;39(3):430-432.
20. Young B, Oldfield EH, Markesbery WR, et al. Reoperation for glioblastoma. J Neurosurg. 1981;55(6):917-921.
21. Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival. J Neurosurg. 2012; 117(6):1032-1038.
22. Chaichana KL, Zadnik P, Weingart JD, et al. Multiple resections for patients with glioblastoma: prolonging survival. J Neurosurg. 2012;118(4):812-820.
23. Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol. 2010;28(24):3838-3843.
24. Johnson DR, O'Neill BP. Glioblastoma survival in the United States before and during the temozolomide era. J Neurooncol. 2012; 107(2):359-364.
25. Ohgaki H, Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol. 2005;64(6): 479-489.
26. Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other salvage therapy. Surg Neurol. 2008;69(5):506-509; discussion 509.
27. Quick J, Gessler F, Dutzmann S, et al. Benefit of tumor resection for recurrent glioblastoma. J Neurooncol. 2014;117(2): 365-372.
28. Keles GE, Lamborn KR, Chang SM, et al. Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy. J Neurosurg. 2004;100(1):41-46.
29. Stummer W, van den Bent MJ, Westphal M. Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion. Acta Neurochirurgica. 2011; 153(6):1211-1218.
30. Balmaceda C, Peereboom D, Pannullo S, et al. Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas. Cancer. 2008;112(5): 1139-1146.
31. Berrocal A, Perez Segura P, Gil M, et al. Extended-schedule dose-Dense temozolomide in refractory gliomas. J Neurooncol. 2010;96(3):417-422.
32. Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma. J Clin Oncol. 2010;28(30):4601-4608.
33. Brandes AA, Tosoni A, Franceschi E, et al. Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO). Cancer Chemother Pharmacol. 2009;64(4):769-775.
34. de Groot JF, Lamborn KR, Chang SM, et al. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol. 2011;29(19): 2689-2695.
35. Fabrini MG, Silvano G, Lolli I, et al. A multi-institutional phase II study on second-line Fotemustine chemotherapy in recurrent glioblastoma. J Neurooncol. 2009;92(1):79-86.
36. Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009;27(28):4733-4740.
37. Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-Alpha2b (pegylated and non-pegylated) in patients with recurrent glioblastoma multiforme. Br J Cancer. 2009;101(4):615-620.
38. Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol. 2010;12(5): 508-516.
39. Kong DS, Lee JI, Kim JH, et al. Phase II trial of low-Dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro Oncol. 2010;12(3):289-296.
40. Kreisl TN, Kim L, Moore K, et al. Phase II trial of single-Agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27(5): 740-745.
41. Narayana A, Kelly P, Golfinos J, et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J Neurosurg. 2009;110(1):173-180.
42. Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. J Clin Oncol. 2010;28(12):2051-2057.
43. Raizer JJ, Grimm S, Chamberlain MC, et al. A phase 2 trial of single-Agent bevacizumab given in an every-3-week schedule for patients with recurrent high-grade gliomas. Cancer. 2010; 116(22):5297-5305.
44. Reardon DA, Desjardins A, Peters KB, et al. Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer. 2011;117(23):5351-5358.
45. Reardon DA, Desjardins A, Vredenburgh JJ, et al. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer. 2009; 101(12):1986-1994.
46. Reardon DA, Fink KL, Mikkelsen T, et al. Randomized phase II study of cilengitide, an integrin-Targeting arginine-glycine-Aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol. 2008; 26(34):5610-5617.
47. Scoccianti S, Detti B, Sardaro A, et al. Second-line chemotherapy with fotemustine in temozolomide-pretreated patients with relapsing glioblastoma: a single institution experience. Anticancer Drugs. 2008;19(6):613-620.
48. van den Bent MJ, Brandes AA, Rampling R, et al. Randomized phase II trial of erlotinib versus temozolomide or carmustine in recurrent glioblastoma: EORTC brain tumor group study 26034. J Clin Oncol. 2009;27(8):1268-1274.
49. Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol. 2010;28(7): 1168-1174.
50. Carson KA, Grossman SA, Fisher JD, et al. Prognostic factors for survival in adult patients with recurrent glioma enrolled onto the new approaches to brain tumor therapy CNS consortium phase I and II clinical trials. J Clin Oncol. 2007;25(18):2601-2606.